Tysabri (natalizumab) is a brand-name intravenous (IV) infusion that’s prescribed for multiple sclerosis. This article covers topics such as side effects, dosage, and how Tysabri works.

Tysabri (natalizumab) helps treat forms of multiple sclerosis and Crohn’s disease. The drug comes as an infusion solution. Tysabri is not safe to receive in pregnancy and may not be safe to ...

A large majority of people with relapsing-remitting multiple sclerosis (RRMS) who received Tysabri (natalizumab) in a real-world setting experienced no evidence of disease activity for as long as ...

Regulators in the US and Europe have started to review Novartis' biosimilar version of Biogen's big-selling multiple sclerosis therapy Tysabri, which could reach the market next year. If approved ...

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

A drug infusion is delivered through an IV needle or catheter, and you have to go sit at a healthcare facility to ... As researchers learn more about MS, different types of therapies are emerging.

Baxter International this week released the first product – 1-liter IV solutions – manufactured post-hurricane at its North Cove, North Carolina facility. The product release is ahead of the ...

every 3 months. Cumulative lifetime dose limit Secondary progressive, progressive relapsing, or worsening RRMS Tysabri® Natalizumab iv. every 28 days RRMS for patients who have had an inadequate ...

The surgery was off because there wasn't enough IV fluid to proceed. "I was having such a hard time processing what she was even saying to me, that I was just really quiet," she says, explaining ...

Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic ...

A Baxter spokesperson confirmed the decision to Fierce Pharma Wednesday, citing a fragmented local IV solutions market and the impact from Hurricane Helene on U.S. supplies. “The fragmented ...

The plant makes 60% of the United States' supply of IV fluids and peritoneal dialysis (PD) solutions, according to the American Hospital Association. Its closure had triggered a shortage of IV ...